What's new in antifungals?

Current Infectious Disease Reports

Volumn 5, Issue 1, 2003, Pages 16-21

  Valgus, John M ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CASPOFUNGIN; CIMETIDINE; CYCLOSPORIN; DIGOXIN; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MACROLIDE; OMEPRAZOLE; PHENYTOIN; POSACONAZOLE; PROTEINASE INHIBITOR; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONYLUREA DERIVATIVE; TACROLIMUS; VINCA ALKALOID; VORICONAZOLE; WARFARIN;

AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CLINICAL TRIAL; CRYPTOCOCCUS NEOFORMANS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FEVER; HUMAN; LIVER DYSFUNCTION; MYCOSIS; NAUSEA; NONHUMAN; REVIEW; SCEDOSPORIUM APIOSPERMUM; VOMITING;

EID: 0038361542     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0060-4     Document Type: Review

References (34)

1. Beck-Sague CM, Jarvis WR: National nosocomial infections surveillance system. Secular trends in epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993, 167:1247-1251.
2. Jarvis WR: Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995, 20:1526-1530.
3. McNeil MM, Nash SL, Hajjeh RA, et al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001, 33:641-647.
4. Trick WE, Fridkin SK, Edwards JR, et al.: Secular trends in hospital-acquired candidemia among intesive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35:627-630.
5. Georgopapadakou NH, Walsh TJ: Antifungal agents:chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996, 40:279-291.
6. Dismukes WE: Introduction to antifungal drugs. Clin Infect Dis 2000, 30:653-657.
7. Wingard JR: Lipid formulation of amphotericin B: are you a lumper or a splitter? Clin Infect Dis 2002, 35:891-895.
8. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
9. Walsh TJ, Pappas P, Winston DJ, et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
10. Ally R, Schurmann D, Kreisel W, et al.: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001, 33:1447-1454.
11. Cacciapuoti A, Loebenberg D, Corcoran E, et al.: In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000, 44:2017-2022.
12. Pfaller MA, Messer SA, Hollis RJ, et al.: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002, 46:1032-1037.
13. Pfaller MA, Messer SA, Hollis RJ, et al.: In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001, 45:2862-2864.
14. Petraitiene R, Petraitis V, Groll AH, et al.: Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001, 45:857-869.
15. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al.: In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002, 46:3298-3300.
16. Nieto L, Northland R, Pittisuttithum M, et al.: Pasaconazole is equivalent to fluconazole in the treatment of oropharyngeal candidiasis. Paper presented at The Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto. September 17-20, 2000.
17. Hachem RY, Raad I, Afif, et al.: An open, non-comparative multicenter study to evaluate the efficacy and safety of Posaconazole (SCH56592) in the treatment of invasive fungal infections refractory or intolerant to standard therapy. Paper presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto. September 17-20, 2000.
18. Bartizal K, Gill CJ, Abruzzo GK, et al.: In vitro preclinical evaluation studies with the echinicandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997, 41:2326-2332.
19. Chiller T, Farrokhshad K, Brummer E, et al.: Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob Agents Chemother 2000, 44:3302-3305.
20. Chiller T, Farrokhshod K, Brummer E, et al.: The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), and echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 2001, 39:99-103.
21. Poeta MD, Schell WA, Perfect JR: In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997, 41:1835-1836.
22. Arikan S, Lozano-Chiu M, Paetznick V, et al.: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001, 45:327-330.
23. Abruzzo GK, Gill CJ, Flattery AM, et al.: Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000, 44:2310-2318.
24. Abruzzo GK, Flattery AM, Gill CJ, et al.: Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997, 41:2333-2338.
25. Vazquez JA, Lynch M, Boikov D, et al.: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997, 41:1612-1614.
26. Barchiesi F, Schimizzi AM, Fothergill AW, et al.: In vitro activity of a new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999, 18:302-304.
27. Graybill JR, Najvar LK, Luther MF, et al.: Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother 1997, 41:1775-1777.
28. Feldmesser M, Kress Y, Mednick A: The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000, 182:1791-1795.
29. Franzot SP, Casadevall A: Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997, 41:331-336.
30. Maertens J, Raad I, Sable CA, et al.: Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin lipid formulations, or azoles. Paper presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto. September 17-20, 2000.
31. Villanueva A, Gotuzzo E, Arathoon EG, et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002, 113:294-299.
32. Villnueva A, Arathoon EG, Gotuzzo E, et al.: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001, 33:1529-1535.
33. Arathoon EG, Gotuzzo E, Noriega LM, et al.: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002, 46:451-457.
34. Rubin MA, Carroll KC, Cahill BC: Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002, 34:1160-1161.